Oxford Global Biomarkers & Precision Medicine 2025

BRONZE SPONSOR

Biomarkers & Precision Medicine UK 2025 takes place 30 September–1 October at the QEII Centre in London, marking the 20th year of Oxford Global’s flagship conference. The event brings together leading scientists, pharma and biotech innovators, diagnostics experts, and translational researchers to advance biomarker discovery, validation, and clinical application.

For Alamar, this is a key forum to connect with the biomarker community. Our mission is to equip researchers with tools to reliably measure low-abundance biomarkers in blood and other fluids — enabling breakthroughs in neurodegeneration, inflammation, and disease progression. The discussions at this event mirror the challenges we address every day: detection sensitivity and assay validation, that drive discovery forward.

Visit us at Booth #37

SPONSORED TALK

TRACK 1 | Biomarkers identification & Validation: Neuroscience & Co-Morbidity

Wednesday, 01 October | 14:30-14:55 BST

Conference Room 1

Novel blood-based proteomic signatures across multiple neurodegenerative diseases

Dr. Malpetti will share how multiplex proteomic analysis of Cambridge-based cohorts is advancing our understanding of neurodegeneration and inflammation in conditions beyond Alzheimer’s disease, including frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP). She will highlight how blood biomarkers such as pTau, NfL, and inflammation markers are reshaping our view of disease progression, multi-etiology dementia, and survival prediction.

Attendees will gain valuable insight into the translational impact of large-scale proteomic screening and how highly sensitive blood-based assays can drive earlier detection and more precise disease monitoring across multiple neurodegenerative disorders.

Maura Malpetti, PhD.
Race Against Dementia ARUK Fellow, Senior Research Associate
UK DRI at Cambridge
Visit Conference Site
Linkedin

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Linkedin

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.